Massive point of difference in current process for unnecessary...

Massive point of difference in current process for unnecessary ambulance and hospitalisation. This was a market that I didn't even think off so they might as well include this in the pilot since RAP are still waiting for the UK feasibility study of ResAppDx-EU use in ED which has already received medical board approval to commence.

Telehealth, clinic and ED were already big market and now RCA and mining sector, RAP should also look at child care since ResAppDx-EU can be used for all age demographic.